22 related articles for article (PubMed ID: 2106417)
1. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
Sauermann R; Delle-Karth G; Marsik C; Steiner I; Zeitlinger M; Mayer-Helm BX; Georgopoulos A; Müller M; Joukhadar C
Antimicrob Agents Chemother; 2005 Feb; 49(2):650-5. PubMed ID: 15673747
[TBL] [Abstract][Full Text] [Related]
2. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
Brogden RN; Spencer CM
Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677
[TBL] [Abstract][Full Text] [Related]
4. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
5. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.
Piédrola G; Galan I; Leyva A; Maroto MC
Drugs; 1988; 35 Suppl 2():62-4. PubMed ID: 3135171
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina.
Casellas JM; Goldberg M; Orellana N; Morosini MI; Negri MC; Arduino S
Infection; 1990; 18(3):193-5. PubMed ID: 2114372
[TBL] [Abstract][Full Text] [Related]
8. Animal models as predictors of outcome of therapy with broad spectrum cephalosporins.
Rouse MS; Tallan BM; Henry NK; Steckelberg JM; Wilson WR
J Antimicrob Chemother; 1992 Apr; 29 Suppl A():39-45. PubMed ID: 1601755
[TBL] [Abstract][Full Text] [Related]
9. The role of cefotaxime in the treatment of surgical infections.
Wittmann DH
Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
[TBL] [Abstract][Full Text] [Related]
10. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
Craig WA
Diagn Microbiol Infect Dis; 1995; 22(1-2):89-96. PubMed ID: 7587056
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory and bactericidal activity of cefpirome and cefotaxime against blood culture isolates.
Ansorg R; Primavesi CA; von Recklinghausen G
Chemotherapy; 1990; 36(1):24-8. PubMed ID: 2106417
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
